Quince Therapeutics, Inc.
QNCX
$1.04
-$0.01-0.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -31.62% | -22.15% | 10.97% | 29.93% | -26.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.22% | 40.24% | 58.35% | 22.92% | -7.53% |
| Operating Income | -30.22% | -40.24% | -58.35% | -22.92% | 7.53% |
| Income Before Tax | -40.80% | -2.39% | -466.78% | 11.07% | -59.79% |
| Income Tax Expenses | -86.27% | -- | -- | 112.50% | -- |
| Earnings from Continuing Operations | -40.07% | -2.64% | -467.52% | 9.02% | -60.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.07% | -2.64% | -467.52% | 9.02% | -60.72% |
| EBIT | -30.22% | -40.24% | -58.35% | -22.92% | 7.53% |
| EBITDA | -37.08% | -38.83% | -57.59% | -22.65% | 11.76% |
| EPS Basic | -31.58% | 14.23% | -373.09% | 24.17% | -39.55% |
| Normalized Basic EPS | -59.88% | -20.50% | -35.29% | -3.30% | 29.81% |
| EPS Diluted | -31.58% | 14.23% | -373.09% | 24.17% | -39.55% |
| Normalized Diluted EPS | -59.88% | -20.50% | -35.29% | -3.30% | 29.81% |
| Average Basic Shares Outstanding | 6.45% | 19.66% | 19.99% | 19.96% | 15.16% |
| Average Diluted Shares Outstanding | 6.45% | 19.66% | 19.99% | 19.96% | 15.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |